4522167
Last Update Posted: 2023-06-29
Recruiting has ended
All Genders accepted | 50 Years + |
434 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
This is a randomized, double-masked, multicenter study to evaluate the efficacy and safety of FYB203 compared to Eylea® in patients with neovascular age related macular degeneration.
Eligibility
Relevant conditions:
Neovascular Age-related Macular Degeneration
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov